Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELUXA 2
2015-005079-26Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of olmutinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Boehringer Ingelheim. Started May 2016; status: completed.
02
Drugs
olmutinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2015-005079-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005079-26.